Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
14.33
+0.13 (0.92%)
At close: Dec 5, 2025, 4:00 PM EST
14.77
+0.44 (3.07%)
After-hours: Dec 5, 2025, 6:37 PM EST
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Atara Biotherapeutics stock have an average target of 21, with a low estimate of 17 and a high estimate of 25. The average target predicts an increase of 46.55% from the current stock price of 14.33.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 11, 2025.
Analyst Ratings
The average analyst rating for Atara Biotherapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +18.63% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 22, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | +18.63% | Jan 17, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +74.46% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
123.54M
from 128.94M
Decreased by -4.19%
Revenue Next Year
59.10M
from 123.54M
Decreased by -52.16%
EPS This Year
2.14
from -11.41
EPS Next Year
-0.28
from 2.14
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 130.2M | 76.7M | ||||
| Avg | 123.5M | 59.1M | ||||
| Low | 116.8M | 43.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.0% | -38.0% | ||||
| Avg | -4.2% | -52.2% | ||||
| Low | -9.4% | -64.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.59 | 0.91 | ||||
| Avg | 2.14 | -0.28 | ||||
| Low | 1.69 | -0.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -57.3% | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.